Successful epoprostenol withdrawal in pulmonary arterial hypertension: Case report and literature review

Eftychia A. Demerouti, Athanassios N. Manginas, George D. Athanassopoulos, George T. Karatasakis, Evangelos D. Leontiadis, Gregory S. Pavlides

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pulmonary arterial hypertension is a rare and devastating disease characterized by vascular proliferation and remodeling. Epoprostenol, the drug counterpart of the eicosanoid prostacyclin, produced by the vascular endothelial cells, is the drug of choice for this disease. Its capacity to act rapidly and to significantly improve survival prospects in severe pulmonary hypertension patients has been supported by a wealth of evidence. Intravenous epoprostenol was believed to require therapy of indefinite duration. Since 2001, oral drugs have been approved for specific treatment. The availability of newer and less invasive drug therapies for pulmonary arterial hypertension led physicians to withdraw epoprostenol in carefully selected patients. We report a case of successful intravenous epoprostenol interruption in a patient with idiopathic disease. A literature review on epoprostenol withdrawal in pulmonary hypertension in adult patients is also provided.

Original languageEnglish (US)
Pages (from-to)e1-e5
JournalRespiratory Care
Volume58
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Epoprostenol
Pulmonary Hypertension
Pharmaceutical Preparations
Eicosanoids
Rare Diseases
Endothelial Cells
Physicians
Drug Therapy
Survival
Therapeutics

Keywords

  • Prostanoids
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Demerouti, E. A., Manginas, A. N., Athanassopoulos, G. D., Karatasakis, G. T., Leontiadis, E. D., & Pavlides, G. S. (2013). Successful epoprostenol withdrawal in pulmonary arterial hypertension: Case report and literature review. Respiratory Care, 58(2), e1-e5. https://doi.org/10.4187/respcare.01752

Successful epoprostenol withdrawal in pulmonary arterial hypertension : Case report and literature review. / Demerouti, Eftychia A.; Manginas, Athanassios N.; Athanassopoulos, George D.; Karatasakis, George T.; Leontiadis, Evangelos D.; Pavlides, Gregory S.

In: Respiratory Care, Vol. 58, No. 2, 01.01.2013, p. e1-e5.

Research output: Contribution to journalArticle

Demerouti, EA, Manginas, AN, Athanassopoulos, GD, Karatasakis, GT, Leontiadis, ED & Pavlides, GS 2013, 'Successful epoprostenol withdrawal in pulmonary arterial hypertension: Case report and literature review', Respiratory Care, vol. 58, no. 2, pp. e1-e5. https://doi.org/10.4187/respcare.01752
Demerouti, Eftychia A. ; Manginas, Athanassios N. ; Athanassopoulos, George D. ; Karatasakis, George T. ; Leontiadis, Evangelos D. ; Pavlides, Gregory S. / Successful epoprostenol withdrawal in pulmonary arterial hypertension : Case report and literature review. In: Respiratory Care. 2013 ; Vol. 58, No. 2. pp. e1-e5.
@article{66ff9bc53ff84aef8385da40bb08e95f,
title = "Successful epoprostenol withdrawal in pulmonary arterial hypertension: Case report and literature review",
abstract = "Pulmonary arterial hypertension is a rare and devastating disease characterized by vascular proliferation and remodeling. Epoprostenol, the drug counterpart of the eicosanoid prostacyclin, produced by the vascular endothelial cells, is the drug of choice for this disease. Its capacity to act rapidly and to significantly improve survival prospects in severe pulmonary hypertension patients has been supported by a wealth of evidence. Intravenous epoprostenol was believed to require therapy of indefinite duration. Since 2001, oral drugs have been approved for specific treatment. The availability of newer and less invasive drug therapies for pulmonary arterial hypertension led physicians to withdraw epoprostenol in carefully selected patients. We report a case of successful intravenous epoprostenol interruption in a patient with idiopathic disease. A literature review on epoprostenol withdrawal in pulmonary hypertension in adult patients is also provided.",
keywords = "Prostanoids, Pulmonary hypertension",
author = "Demerouti, {Eftychia A.} and Manginas, {Athanassios N.} and Athanassopoulos, {George D.} and Karatasakis, {George T.} and Leontiadis, {Evangelos D.} and Pavlides, {Gregory S.}",
year = "2013",
month = "1",
day = "1",
doi = "10.4187/respcare.01752",
language = "English (US)",
volume = "58",
pages = "e1--e5",
journal = "Respiratory Care",
issn = "0098-9142",
publisher = "Daedalus Enterprises Inc.",
number = "2",

}

TY - JOUR

T1 - Successful epoprostenol withdrawal in pulmonary arterial hypertension

T2 - Case report and literature review

AU - Demerouti, Eftychia A.

AU - Manginas, Athanassios N.

AU - Athanassopoulos, George D.

AU - Karatasakis, George T.

AU - Leontiadis, Evangelos D.

AU - Pavlides, Gregory S.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Pulmonary arterial hypertension is a rare and devastating disease characterized by vascular proliferation and remodeling. Epoprostenol, the drug counterpart of the eicosanoid prostacyclin, produced by the vascular endothelial cells, is the drug of choice for this disease. Its capacity to act rapidly and to significantly improve survival prospects in severe pulmonary hypertension patients has been supported by a wealth of evidence. Intravenous epoprostenol was believed to require therapy of indefinite duration. Since 2001, oral drugs have been approved for specific treatment. The availability of newer and less invasive drug therapies for pulmonary arterial hypertension led physicians to withdraw epoprostenol in carefully selected patients. We report a case of successful intravenous epoprostenol interruption in a patient with idiopathic disease. A literature review on epoprostenol withdrawal in pulmonary hypertension in adult patients is also provided.

AB - Pulmonary arterial hypertension is a rare and devastating disease characterized by vascular proliferation and remodeling. Epoprostenol, the drug counterpart of the eicosanoid prostacyclin, produced by the vascular endothelial cells, is the drug of choice for this disease. Its capacity to act rapidly and to significantly improve survival prospects in severe pulmonary hypertension patients has been supported by a wealth of evidence. Intravenous epoprostenol was believed to require therapy of indefinite duration. Since 2001, oral drugs have been approved for specific treatment. The availability of newer and less invasive drug therapies for pulmonary arterial hypertension led physicians to withdraw epoprostenol in carefully selected patients. We report a case of successful intravenous epoprostenol interruption in a patient with idiopathic disease. A literature review on epoprostenol withdrawal in pulmonary hypertension in adult patients is also provided.

KW - Prostanoids

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=84873633748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873633748&partnerID=8YFLogxK

U2 - 10.4187/respcare.01752

DO - 10.4187/respcare.01752

M3 - Article

C2 - 22710078

AN - SCOPUS:84873633748

VL - 58

SP - e1-e5

JO - Respiratory Care

JF - Respiratory Care

SN - 0098-9142

IS - 2

ER -